WINDLAS logo

Windlas Biotech Limited Stock Price

NSEI:WINDLAS Community·₹17.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

WINDLAS Share Price Performance

₹854.05
-145.30 (-14.54%)
₹854.05
-145.30 (-14.54%)
Price ₹854.05

WINDLAS Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet second-rate dividend payer.

1 Risk
2 Rewards

Windlas Biotech Limited Key Details

₹8.7b

Revenue

₹5.4b

Cost of Revenue

₹3.3b

Gross Profit

₹2.6b

Other Expenses

₹667.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
31.85
38.03%
7.68%
4.8%
View Full Analysis

About WINDLAS

Founded
2001
Employees
1346
CEO
Komal Gupta
WebsiteView website
windlas.com

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

Recent WINDLAS News & Updates

Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From Overpricing

Jan 17
Windlas Biotech Limited's (NSE:WINDLAS) Popularity With Investors Is Under Threat From Overpricing

Recent updates

No updates